Video

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

One of the most significant changes in the guidelines is that duel-targeting of the HER2-pathway for patients with operable HER2-positive breast cancer is now recommended, says Gradishar. This change was based on the NeoSphere trial, which showed that the use of pertuzumab and trastuzumab with chemotherapy improved pathological complete response versus other regimens. This may lead to improved outcomes overall, says Gradishar.

In hormone receptor-positive metastatic disease, the guidelines now recommend endocrine therapy combined with targeted agents instead of just endocrine therapy alone, says Gradishar. In trials, this combination has translated into a marked improvement in progression-free survival.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Andrew Davis, MD
Adrienne G. Waks, MD, Dana-Farber Cancer Institute
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"
Video 7 - 2 KOLs are featured in, "Adverse Event Data and Management for Optimal Quality of Life in HR+/HER2- mBC"
2 KOLs are featured in this program.
2 KOLs are featured in this program.
A panel of 5 experts on breast cancer